title: Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?
abstract: Evaluation of: Pellagatti A, Benner A, Mills KI et al. Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. J. Clin. Oncol. 31(28), 3557-3564 (2013). Patients with myelodysplastic syndromes (MDS) exhibit wide heterogeneity in clinical outcomes making accurate risk-stratification an integral part of the risk-adaptive management paradigm. Current prognostic schemes for MDS rely on clinicopathological parameters. Despite the increasing knowledge of the genetic landscape of MDS and the prognostic impact of many newly discovered molecular aberrations, none to date has been incorporated formally into the major risk models. Efforts are ongoing to use data generated from genome-wide high-throughput techniques to improve the 'individualized' outcome prediction for patients. We here discuss an important paper in which gene expression profiling (GEP) technology was applied to marrow CD34(+) cells from 125 MDS patients to generate and validate a standardized GEP-based prognostic signature.
authors.affiliation: Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
authors.forename: Amer M
authors.initials: AM
authors.lastname: Zeidan
authors.forename: Thomas
authors.initials: T
authors.lastname: Prebet
authors.forename: Ehab
authors.initials: E
authors.lastname: Saad Aldin
authors.forename: Steven David
authors.initials: SD
authors.lastname: Gore
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D005260:Female; D020869:Gene Expression Profiling; D006412:Hematopoietic Stem Cells / Q000378:metabolism*; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000175:diagnosis*; D014411:Neoplastic Stem Cells / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor